Verastem (VSTM) Gains from Investment Securities (2012 - 2026)
Verastem (VSTM) recorded quarterly Gains from Investment Securities of -$9.3 million in Q1 2026, up 75.33% quarter-over-quarter from -$37.8 million in Q4 2025, and down 485.89% on a YoY basis from $2.4 million in Q1 2025.
Verastem (VSTM) Gains from Investment Securities (2012 - 2026) Analysis & Trends
Verastem's Gains from Investment Securities history runs 15 years deep, the most recent figure standing at -$9.3 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 485.89% year-over-year to -$9.3 million; the TTM figure through Mar 2026 stood at -$25.5 million (down 158.66% YoY), while the FY2025 annual figure was $3.0 million, up 22.24% from the prior year.
- Gains from Investment Securities was -$9.3 million for Q1 2026 at Verastem, up from -$37.8 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $19.1 million in Q4 2024 to a low of -$37.8 million in Q4 2025.
- Historically, Gains from Investment Securities has averaged $302096.5 across 5 years, with a median of $603330.0 in 2024.
- The sharpest annual moves came in 2022 and 2026: Gains from Investment Securities soared 116910.5% in 2022, then tumbled 485.89% in 2026.
- A 5-year view of Gains from Investment Securities shows it stood at $1.2 million in 2022, then soared by 94.36% to $2.3 million in 2023, then soared by 743.43% to $19.1 million in 2024, then slumped by 297.36% to -$37.8 million in 2025, then soared by 75.33% to -$9.3 million in 2026.
- The last three Gains from Investment Securities figures came in at -$9.3 million (Q1 2026), -$37.8 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.32 Mn |
| Mar 31, 2026 | -9.32 Mn |
| Dec 31, 2025 | -37.79 Mn |
| Dec 31, 2025 | -37.79 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | 554,500.00 |
| Jun 30, 2025 | 554,500.00 |
| Mar 31, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 19.15 Mn |
| Dec 31, 2024 | 19.15 Mn |
| Sep 30, 2024 | 13.50 Mn |
| Sep 30, 2024 | 13.50 Mn |
| Jun 30, 2024 | 184,122.00 |
| Jun 30, 2024 | 184,122.00 |
| Mar 31, 2024 | 603,330.00 |
| Mar 31, 2024 | 603,330.00 |
| Dec 31, 2023 | 2.27 Mn |
| Dec 31, 2023 | 2.27 Mn |